Tech Session VII: Gene Delivery and Gene Editing IV
Polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics
Friday, July 18, 2025
8:54 AM – 9:05 AM EDT
Introduction: Lipid nanoparticles (LNPs) represent the most promising synthetic delivery system class due to their clinical use in siRNA liver therapy and mRNA COVID-19 vaccines. However, recent reports suggest that the generation of anti-PEG antibodies (APAs) after receiving PEGylated therapeutics limits efficacy when re-administered. Specific APA related phagocytosis was enhanced, leading to accelerated blood clearance of re-administered PEGylated drugs that weakens therapy. Thus, LNP neutralization by existing APAs raises concerns for LNP-mediated therapies that require multiple administrations.
Learning Objectives:
At the completion of this activity, participants will know
developed LNPs with low immunogenicity to overcome current roadblocks to nucleic acid medicines
revealed that polymer physicochemical properties and architecture improved repeated dose efficacy
Demonstrated that brush-shaped polymer lipids generated superior therapeutic outcomes
